申请人:Nikken Chemicals Company, Limited
公开号:EP1410795A1
公开(公告)日:2004-04-21
An agent for the treatment of allergic eye disease containing a 3-anilino-2-cycloalkenone derivative having the formula (I):
wherein R1 is an unsubstituted or substituted C1 to C8 alkyl group provided that an unsubstituted methyl group is excluded, a C3 to C7 cycloalkyl group, a C6 to C10 bicycloalkyl group or an indanyl group, etc., R2 is a C1 to C4 alkyl group, R3 is a hydrogen atom, a C1 to C5 alkyl group, a C3 to C7 cycloalkyl group, etc., R4 is a hydrogen atom, an unsubstituted or substituted C1 to C5 alkyl group, a halogen atom, etc., R5, R6, R7 and R8 are independently a hydrogen atom, a C1 to C5 alkyl group, etc., X is -(CR11R12)n- or NR13-, wherein n is 0 to 2, R11, R12 and R13 are independently a hydrogen atom, a C1 to C5 alkyl group, etc.
一种治疗过敏性眼病的制剂,含有具有式(I)的3-苯胺基-2-环烯酮衍生物:
其中 R1 是未取代或取代的 C1 至 C8 烷基(但不包括未取代的甲基)、C3 至 C7 环烷基、C6 至 C10 双环烷基或茚基等,R2 是 C1 至 C4 烷基,R3 是氢原子、C1 至 C5 烷基、C3 至 C7 环烷基等、R4 是氢原子、未取代或取代的 C1 至 C5 烷基、卤素原子等,R5、R6、R7 和 R8 独立地是氢原子、C1 至 C5 烷基等,X 是-(CR11R12)n- 或 NR13-,其中 n 是 0 至 2,R11、R12 和 R13 独立地是氢原子、C1 至 C5 烷基等。